Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

Medical staff in Western Australia have been warned after reports of the wrong immunisations being given to patients.

The WA Department of Health has sent an urgent reminder to medical staff to make sure they’re giving patients the right RSV ...

The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

Find patient medical information for Abrysvo (respiratory syncytial virus vaccine) on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings ...

Research shows RSV leads to high hospitalization rates in adults, emphasizing the importance of enhanced surveillance and ...

Positive topline data were announced from a phase 3 study evaluating Abrysvo ® (respiratory syncytial virus [RSV] vaccine) in immunocompromised adults.. Substudy B of the MONeT trial ...

This Abrysvo or Arexvy market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the ...

Today, Pfizer Canada ULC announced that ABRYSVO™ has been selected as the publicly-funded vaccine for the prevention of Respiratory Syncytial Virus (RSV) in older adults in Canada for 2024-2025.